Overview

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

Status:
Terminated

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c. injections of Enoxaparin for the primary prevention of Venous Thromboembolic Events [VTE] in patients hospitalized for acute medical illness. The secondary objectives were to evaluate the safety of AVE5026 and to document AVE5026 exposure in this population.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Enoxaparin
Enoxaparin sodium
Heparin, Low-Molecular-Weight
Semuloparin